DOSES OF PANOBINOSTAT FOR MULTIPLE MYELOMA Russian patent published in 2020 - IPC A61K31/4045 A61K31/573 A61K31/69 A61P35/00 G01N33/48 

FIELD: medicine.

SUBSTANCE: invention relates to a method of treating a human patient having multiple myeloma. Proposed method comprises administering an initial dose of 15 mg of panobinostat or its pharmaceutically acceptable salt to a patient if the patient has mild hepatic impairment; or an initial dose of 10 mg of panobinostat or a pharmaceutically acceptable salt thereof if the patient has moderate hepatic impairment. Mild hepatic insufficiency is bilirubin ≤ 1 × upper limit of normal range ("ULN") and aspartate aminotransferase ("AST") > 1 × ULN or bilirubin > 1.0–1.5 × ULN and any amount of AST above ULN is present; moderate hepatic insufficiency is bilirubin> 1.5–3.0 × ULN and any amount of AST above ULN is present.

EFFECT: doses of panobinostat for multiple myeloma are improved with respect to safety, selectivity in patients, response to undesirable phenomena and interactions between drugs, which enables to use panobinostat for a greater number of patients, particularly in combination with another agent for treating multiple myeloma and thereby increase patient's chances of completing their dosing cycles and clinical benefit, such as a longer disease-free progression.

29 cl, 6 tbl, 1 dwg